Cancer Staging TNM Reference
Comprehensive TNM staging system reference for cancer classification and stage grouping
Determine Stage Group
Note: Specific staging criteria vary by cancer type. Consult AJCC Cancer Staging Manual for details.
TNM Classification
T1 N0 M0
Stage Group
Stage I
Description:
Early stage - Small tumor, no lymph node involvement
General Prognosis:
Very good - Usually curable with surgery ± adjuvant therapy
Important Note
This is a simplified general staging reference. Actual staging criteria are highly specific to each cancer type and may include additional factors such as grade, biomarkers, and histologic subtypes. Always consult the current AJCC Cancer Staging Manual (8th Edition or newer) for precise staging criteria.
TNM Classification Components
T - Primary Tumor
| Category | Description |
|---|---|
| TX | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | Carcinoma in situ (non-invasive cancer) |
| T1 | Small tumor with minimal invasion (specific size varies by cancer type) |
| T2 | Larger tumor or greater degree of invasion |
| T3 | Extensive local invasion of surrounding tissues |
| T4 | Tumor invades adjacent structures or organs |
Note: T categories may have subcategories (e.g., T1a, T1b) with specific size cutoffs that vary by cancer type.
N - Regional Lymph Nodes
| Category | Description |
|---|---|
| NX | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Limited regional lymph node involvement (specific criteria vary) |
| N2 | Moderate regional lymph node involvement |
| N3 | Extensive regional lymph node involvement |
Note: N categories are based on number, size, and location of involved nodes. Criteria vary significantly by cancer type.
M - Distant Metastasis
| Category | Description |
|---|---|
| M0 | No distant metastasis |
| M1 | Distant metastasis present |
Note: M1 may have subcategories (M1a, M1b, M1c) specifying location of metastases in some cancer types.
General Stage Grouping
| Stage | Description | General Characteristics |
|---|---|---|
| Stage 0 | Carcinoma in situ | Abnormal cells present but not invasive; no spread |
| Stage I | Early stage cancer | Small tumor, localized, no lymph node involvement |
| Stage II | Localized cancer | Larger tumor or minimal lymph node involvement |
| Stage III | Regionally advanced | Extensive local invasion or significant nodal involvement |
| Stage IV | Metastatic cancer | Cancer has spread to distant organs |
Cancer-Specific Staging Examples
Breast Cancer
- T1: Tumor ≤20 mm (further subdivided: T1mi, T1a, T1b, T1c)
- T2: Tumor >20 mm but ≤50 mm
- T3: Tumor >50 mm
- T4: Extension to chest wall or skin
- N1: 1-3 positive axillary nodes
- Staging also incorporates grade, ER/PR/HER2 status
Lung Cancer (Non-Small Cell)
- T1: Tumor ≤3 cm, surrounded by lung or visceral pleura
- T2: Tumor >3 cm but ≤5 cm or involving main bronchus
- T3: Tumor >5 cm but ≤7 cm or invading certain structures
- T4: Tumor >7 cm or invading mediastinum, heart, great vessels
- N categories based on specific lymph node stations
Colorectal Cancer
- T1: Tumor invades submucosa
- T2: Tumor invades muscularis propria
- T3: Tumor invades through muscularis propria into subserosa/pericolonic tissues
- T4: Tumor perforates visceral peritoneum or invades other organs
- N1: 1-3 regional nodes positive; N2: 4+ nodes positive
Melanoma
- T1: Melanoma ≤1.0 mm thickness
- T2: Melanoma >1.0 mm but ≤2.0 mm
- T3: Melanoma >2.0 mm but ≤4.0 mm
- T4: Melanoma >4.0 mm
- Staging incorporates ulceration and mitotic rate
- N staging based on number of nodes and presence of in-transit metastases
Additional Staging Factors
Grade (G)
- GX: Grade cannot be assessed
- G1: Well differentiated (low grade)
- G2: Moderately differentiated (intermediate grade)
- G3: Poorly differentiated (high grade)
- G4: Undifferentiated (high grade)
Residual Tumor (R)
- R0: Complete resection, negative margins
- R1: Microscopic residual tumor
- R2: Macroscopic residual tumor
Lymphovascular Invasion (L, V)
- L0/V0: No lymphatic or venous invasion
- L1/V1: Invasion present
- Important prognostic factor in many cancers
Biomarkers
- ER/PR/HER2 status in breast cancer
- PD-L1 expression in lung cancer
- MSI-H/dMMR status in colorectal cancer
- BRAF mutation in melanoma
- PSA level in prostate cancer
Frequently Asked Questions
What does TNM stand for?
TNM stands for Tumor, Nodes, and Metastasis. It is the most widely used cancer staging system, developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC). The system describes the extent of the primary tumor (T), involvement of regional lymph nodes (N), and presence of distant metastases (M).
Why is cancer staging important?
Cancer staging is crucial for treatment planning, predicting prognosis, facilitating communication among healthcare providers, and stratifying patients for clinical trials. It helps determine whether surgery is feasible, what type of systemic therapy is appropriate, and provides patients with information about expected outcomes.
What is the difference between clinical and pathologic staging?
Clinical staging (cTNM) is based on physical examination, imaging, and biopsy before treatment. Pathologic staging (pTNM) incorporates information from surgical resection and pathologic examination of the specimen. Pathologic staging is generally more accurate but only available for patients who undergo surgery.
Does the stage change over time?
No. The stage assigned at diagnosis does not change, even if the cancer progresses or responds to treatment. This allows for consistent prognostic information and outcome comparisons. However, if cancer recurs or a new primary develops, it will be staged separately.
What is restaging?
While the original stage doesn't change, cancers may be "restaged" for treatment planning purposes, particularly after neoadjuvant therapy (chemotherapy or radiation before surgery). This is denoted with a "y" prefix (e.g., ypT2N0) to indicate post-treatment staging.
Are staging criteria the same for all cancers?
No. While the TNM framework is consistent, specific criteria for each T, N, and M category vary significantly by cancer type. For example, a T1 breast cancer is defined differently than a T1 lung cancer. Always consult the AJCC Cancer Staging Manual for cancer-specific criteria.
What is the AJCC Cancer Staging Manual?
The AJCC Cancer Staging Manual is the authoritative reference for cancer staging, currently in its 8th edition (published 2017). It provides detailed, cancer-specific staging criteria based on extensive data analysis. The manual is updated approximately every 7-8 years to incorporate new scientific evidence.
How does staging affect treatment decisions?
Staging guides treatment selection. Early-stage cancers (I-II) may be treated with surgery alone or surgery plus adjuvant therapy. Locally advanced cancers (III) often require multimodality treatment. Metastatic cancers (IV) are typically treated with systemic therapy, with surgery reserved for palliation or specific clinical scenarios.
Related Calculators
BSA Chemotherapy Calculator
Calculate body surface area for chemotherapy dosing
Creatinine Clearance Chemotherapy Calculator
Calculate CrCl and carboplatin dosing
Febrile Neutropenia Risk Calculator
MASCC Risk Index for chemotherapy patients
Palliative Prognostic Score
Predict 30-day survival in palliative care
Child-Pugh Calculator
Assess severity of liver cirrhosis
Duke Treadmill Score
Assess cardiovascular disease prognosis
Understanding the TNM Cancer Staging System
The TNM staging system is the most comprehensive and widely used method for classifying the extent of cancer spread. Developed by the American Joint Committee on Cancer (AJCC) in collaboration with the Union for International Cancer Control (UICC), it provides a standardized framework for describing cancer progression that is used globally by oncologists, surgeons, radiation oncologists, and researchers.
The Three Pillars of TNM
The system is built on three fundamental components. T (Tumor) describes the size and extent of the primary tumor, including its invasion into surrounding tissues. N (Nodes) indicates whether cancer has spread to regional lymph nodes and, if so, how many nodes are involved and their location. M (Metastasis) denotes whether cancer has spread to distant organs or lymph nodes beyond the regional area. Together, these three components provide a comprehensive picture of cancer extent.
Clinical vs. Pathologic Staging
Cancer staging can occur at different time points using different information sources. Clinical staging (designated with a lowercase "c" before the TNM classification, as in cT2N1M0) is performed before any treatment and relies on physical examination, imaging studies (CT, MRI, PET scans), and biopsies. Pathologic staging (designated with a lowercase "p," as in pT2N1M0) incorporates findings from surgical resection and detailed pathologic examination of the removed tissue. Pathologic staging is generally more accurate because it allows direct examination of the tumor and lymph nodes, but it is only available for patients who undergo surgery.
Stage Grouping and Prognosis
The specific TNM categories are combined into stage groups (0, I, II, III, IV) that provide simplified categories for treatment planning and prognostic discussions. Generally, stage I represents early, localized cancer with the best prognosis. Stages II and III represent progressively larger tumors or regional lymph node involvement with intermediate prognosis. Stage IV indicates metastatic disease, which is usually incurable with current treatments, though some patients may achieve long-term survival with modern therapies.
Cancer-Specific Criteria
While the TNM framework is consistent across cancer types, the specific definitions of each category are highly cancer-specific. A T1 breast cancer (tumor 20 mm or smaller) is defined very differently from a T1 melanoma (1.0 mm thickness or less). Similarly, lymph node staging criteria vary based on the anatomy and lymphatic drainage patterns of different organs. This specificity allows the staging system to accurately reflect the biological behavior and prognosis of each cancer type.
Evolution of Staging Criteria
The AJCC Cancer Staging Manual is updated approximately every 7-8 years to incorporate new scientific evidence. The current 8th edition, published in 2017, introduced significant changes for many cancers. For example, breast cancer staging now incorporates tumor grade and biomarker status (ER, PR, HER2), recognizing that biological features are as important as anatomic extent. Melanoma staging was revised to better reflect the impact of ulceration and mitotic rate. These updates ensure that staging remains clinically relevant and prognostically accurate.
Additional Prognostic Factors
Beyond the basic TNM classification, modern staging incorporates additional factors that affect prognosis and treatment. Tumor grade (degree of differentiation) is important across many cancer types, with poorly differentiated tumors having worse outcomes. Biomarkers such as hormone receptors in breast cancer, PD-L1 expression in lung cancer, and microsatellite instability in colorectal cancer influence treatment selection and prognosis. Lymphovascular invasion, perineural invasion, and margin status after surgery all provide additional prognostic information.
Practical Applications in Cancer Care
Staging guides virtually every aspect of cancer management. It determines whether a patient is a candidate for curative surgery or should receive systemic therapy first. It influences the type and duration of adjuvant chemotherapy or radiation. It helps oncologists counsel patients about prognosis and expected outcomes. It standardizes communication among multidisciplinary team members and facilitates enrollment in appropriate clinical trials. Accurate staging is thus fundamental to optimal cancer care.
Limitations and Future Directions
While the TNM system is highly sophisticated, it has limitations. It is based on anatomic extent and does not fully capture tumor biology, molecular features, or host factors that affect outcomes. Some cancers with identical TNM stages have vastly different prognoses based on molecular subtypes. Future staging systems will likely incorporate genomic data, circulating tumor DNA, and other biomarkers to provide more personalized prognostic information. However, the TNM framework will likely remain the foundation of cancer staging for the foreseeable future.